phrykt

Lifeward Ltd. (LFWD): who owns it and who trades it

As of Nov 12, 2026, no open-market insider purchases or sales of LFWD were reported in the last 12 months. 1 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 12, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Insider trades

No LFWD insider reported an open-market purchase or sale in the last 12 months.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
–
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

LFWD short interest

Low short interest. 3.1% of LFWD shares are sold short: about 1 share in 32. Over the last 12 reports the number of shares short went down 35%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 87,325 LFWD shares were sold short, 3.1% of the shares outstanding, down 2.6% from the report before. At the average daily volume of 17,420 shares, buying them all back would take about 5.0 trading days (days to cover).

Shares short, % of all shares

3.08%May 15Oct 309.59%

Days to cover

5.0May 15Oct 3025.4

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202687,3253.08%-3%17,4205.0
Oct 15, 202689,6403.17%-7%5,72615.7
Sep 30, 202696,5123.41%-8%4,24622.7
Sep 15, 2026104,8363.70%-7%4,61922.7
Aug 31, 2026112,1423.96%-7%6,11118.4
Aug 14, 2026121,2224.28%-0%6,80017.8
Jul 31, 2026121,8297.97%-7%6,46518.8
Jul 15, 2026131,0128.57%+31%26,7374.9
Jun 30, 2026100,1886.56%-6%6,90214.5
Jun 15, 2026106,3906.96%-14%8,19213.0
May 29, 2026123,4838.08%-8%14,6318.4
May 15, 2026133,6188.74%-4%7,18418.6

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Lifeward company events

Lifeward filed 28 reports on Form 8-K in the last 12 months, 13 of them about an important change (leadership, listing). The latest was on Nov 5, 2026.

  1. Nov 5, 2026VoteReported shareholder vote results. Filing
  2. Oct 27, 2026LeadershipThe Board of Directors of Lifeward Ltd. appointed Ronen Tsimerman, age 56, as the Company’s Chief Financial Officer, principal financial officer and principal accounting officer, effective November 1, 2026. Filing
  3. Oct 8, 2026LeadershipAs previously reported in Current Reports on Form 8-K filed with the Securities and Exchange Commission on August 31, 2026 and October 1, 2026, Lifeward Ltd. appointed Rami Aviram as its Chief Financial Officer, principal financial officer and principal accounting officer, effective November 1, 2026. Filing
  4. Oct 1, 2026LeadershipAs previously disclosed in the Current Report on Form 8-K filed by Lifeward Ltd. with the Securities and Exchange Commission on August 31, 2026, Almog Adar’s departure as the Company’s Chief Financial Officer, principal financial officer and principal accounting officer became effective on… Filing
  5. Sep 15, 2026VoteSet dates for shareholder nominations. Filing
  6. Sep 8, 2026AnnouncementShared information with investors. Filing
  7. Aug 31, 2026LeadershipMr. Mark Grant will depart from his positions as the President and Chief Executive Officer of Lifeward Ltd. and as a member of the Company’s Board of Directors, following the Company’s entry into a separation agreement with Mr. Grant on August 31, 2026. Filing
  8. Aug 20, 2026LeadershipDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officer. Filing
  9. Aug 14, 2026LeadershipDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officer. Filing
  10. Jul 7, 2026AgreementAmended and Restated Notes, Warrant & Pre-Funded Warrant As previously disclosed, Lifeward Ltd. entered into a securities purchase agreement with Oramed Pharmaceuticals Inc. and certain investors with Oramed, as collateral agent, pursuant to which the Company agreed to issue to the investors senior… Filing
  11. May 19, 2026AnnouncementLifeward Ltd. announced the appointment of Keith D. Rose, M.D. as Chief Medical Officer of the Company, effective as of May 1, 2026. Filing
  12. May 15, 2026ResultsReleased financial results. Filing
  13. Apr 23, 2026LeadershipPursuant to notice provided on April 20, 2026, Jeannine Lynch’s employment with Lifeward Ltd. as the Vice President of Strategy and Market Access will be terminated, effective May 3, 2026. Filing
  14. Mar 31, 2026AnnouncementAs previously disclosed, Lifeward Ltd. received written notice from the Nasdaq Listing Qualifications Department of the Nasdaq Stock Market LLC stating that the Company, as a result of the resignation of Hadar Levy from the Company’s Board of Directors and its Audit Committee, no longer complied… Filing
  15. Mar 25, 2026LeadershipDr. John William Poduska and Randel Richner, current Class II directors of the Board of Directors of the Company notified the Board of their decision to step down from the Board, effective as of March 25, 2026. Filing
  16. Mar 20, 2026ListingLifeward Ltd. received a notice from the Nasdaq Listing Qualifications Department indicating that, following Hadar Levy’s resignation from the Board of Directors of the Company, which reduced the Audit Committee to two members, the Company no longer complies with the audit committee requirement… Filing
  17. Mar 18, 2026ResultsReleased financial results. Filing
  18. Mar 13, 2026VoteReported shareholder vote results. Filing
  19. Mar 11, 2026AnnouncementLifeward Ltd. received written notice from the Nasdaq Listing Qualifications Hearings Department of the Nasdaq Stock Market LLC stating that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2) by maintaining a minimum closing bid price of the Company’s Ordinary Shares of at… Filing
  20. Mar 2, 2026SharesChanged the rights of its shareholders. Filing
  21. Feb 27, 2026LeadershipHadar Levy, current Class I director of the Board of Directors of Lifeward Ltd. notified the Board of his decision to step down from the Board, effective as of February 24, 2026. Filing
  22. Feb 25, 2026AnnouncementOf this Current Report on Form 8-K is incorporated by reference into this Item 3.02. Filing
  23. Feb 19, 2026AgreementAs previously disclosed, Lifeward Ltd. previously entered into a Secured Promissory Note with Oramed Ltd. pursuant to which, the Company issued to Oramed Ltd. a secured promissory note in the principal amount of $3.0 million, which remains outstanding. Filing
  24. Feb 9, 2026AnnouncementAs previously reported, Lifeward Ltd. received a deficiency letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC on August 5, 2025 indicating that, based on the closing bid price for the last 30 consecutive business days, the Company was not in compliance with the $1.00… Filing
  25. Jan 28, 2026LeadershipLifeward Ltd. filed a Current Report on Form 8-K. Filing
  26. Jan 13, 2026LeadershipDeparture of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers Upon the closing of the Share Purchase Agreement, the Board of Directors of the Company is expected to consist of six (6) members, two (2) of whom will be designated by the Company, two (2) of… Filing
  27. Jan 6, 2026VoteReported shareholder vote results. Filing
  28. Dec 19, 2025LeadershipJoseph Turk, current Class I director of the Board of Directors of Lifeward Ltd. and chairperson of the Board, notified the Board of his decision to step down from the Board, effective as of December 31, 2025. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Lifeward financials

Famous investors that hold LFWD

1 of the 50 well-known investors we track reported holding LFWD in their latest 13F filing. The largest position is Jim Simons's, worth $70.8K.

FundQuarterSharesValueOf portfolioChange
Jim Simons · Renaissance TechnologiesQ3 202610,727$70.8K0.0%-5%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about Lifeward Ltd. (LFWD) stock

Are LFWD insiders buying or selling?

No LFWD insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.

What is the short interest in LFWD?

As of Oct 30, 2026, 87,325 LFWD shares were sold short, 3.1% of the shares outstanding, down 2.6% from the report before. At the average daily volume of 17,420 shares, buying them all back would take about 5.0 trading days (days to cover). See the history.

Which famous investors hold LFWD?

1 of the 50 well-known investors we track reported LFWD in their latest 13F filing, including Jim Simons. The largest position is worth $70.8K. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.